New targeted pill vs. chemotherapy for KRAS G12C lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial compares a new targeted pill (D-1553) against a standard chemotherapy (docetaxel) for people with a specific type of advanced lung cancer (KRAS G12C mutation) whose cancer has stopped responding to first-line immunotherapy and chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread or cannot be removed with surgery.
- Your cancer has a specific genetic change called KRAS G12C (confirmed by a special lab test using a tissue sample).
- You have already tried a type of immunotherapy (like Keytruda or Opdivo) and a platinum chemotherapy, but your cancer got worse or you had bad side effects.
- You have not taken a KRAS G12C-targeted drug or the chemotherapy drug docetaxel before.
- You are generally healthy enough to be up and about (ECOG score 0-1) and expected to live at least 3 more months.
- You are willing to use contraception during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new targeted drugs (IN10018 and D-1553) together as a first treatment for advanced non-squamous lung cancer with a specific KRAS G12C mutation. It compares this combination to standard therapy to see if it works better.
This trial tests a new drug (HS-10370) combined with other cancer treatments for people with advanced lung cancer that has a specific mutation called KRAS G12C. It is for those who have not yet received systemic therapy for their advanced disease.
This trial tests a new drug, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. It's for those who have already tried chemo and immunotherapy, and whose cancer has continued to grow.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
This trial tests a combination of two targeted drugs (JAB-21822 and JAB-3312) compared to standard chemotherapy for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. It is for people who have not yet received any cancer treatment for their advanced disease.
This study tests a new pill (GFH375) against a standard chemotherapy (docetaxel) for advanced lung cancer with a specific KRAS G12D mutation. If you have already tried platinum chemo and an immunotherapy, this trial might offer a new option.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.